Davis Polk Advises Entera Bio Ltd. on Its Initial Public Offering

Davis Polk advised Entera Bio Ltd. on its initial public offering of 1,400,000 ordinary shares and 1,400,000 warrants to purchase up to 700,000 ordinary shares. In addition, Entera Bio Ltd. has granted the underwriters a 30-day option to purchase up to an additional 210,000 ordinary shares and/or 210,000 additional warrants to purchase up to a total of 105,000 ordinary shares. The ordinary shares are listed on the NASDAQ Capital Market under the symbol “ENTX” and the warrants as listed on the NASDAQ Capital Market under the symbol “ENTXW.” 

Based in Jerusalem, Israel, Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. It is initially applying its technology to develop an oral formulation of parathyroid hormone for hypoparathyroidism and osteoporosis.

The Davis Polk corporate team included partners Michael Kaplan and Sophia Hudson and associates Ravi P. Ramchandani and Chris Van Buren. The equity derivatives team included partner John M. Brandow and associate Caitlin L. Wood. The tax team included partner Avishai Shachar and counsel Alon Gurfinkel. The intellectual property and technology team included partner David R. Bauer. The executive compensation team included partner Veronica M. Wissel. Members of the Davis Polk team are based in the New York and London offices.